The Central Protocol and Data Monitoring Office (CPDMO) is a Shared Resource that provides a number of centralized clinical research protocol-related services. The primary objectives of the CPDMO Shared Resource are to support Cancer Center clinical investigators by providing assistance in developing high quality clinical protocols, ensuring that all appropriate institutional and Federal reviews have been accomplished prior to accruing participants, providing standard order sets for therapeutic protocols, ensuring appropriate research participant enrollment via a centralized clinical trial registration system, coordinating efforts to design and develop case report forms, ensuring appropriate scientific review, and monitoring of clinical research studies. The CPDMO is a key component of the Clinical Trials Infrastructure. It was proposed by the Clinical Academic Council and approved by the Director in 1995, replacing the Protocol Office which previously managed clinical research protocols. The CPDMO has grown from 5.5 FTEs to 26 FTEs (including the Investigational Studies Pharmacists) to meet the demands of an every-changing regulatory environment and to meet the institutional commitment to human subjects'protection and data integrity. A centralized research participant enrollment system was fully implemented in 1998, along with monitoring of protocol eligibility for 100% of participants who are enrolled on St. Jude protocols. In 1999, an automated clinical trials database application was installed. A program to monitor our institutional trials for protocol compliance, regulatory compliance and data quality was established in the fall of 2000. Therapeutic and non-therapeutic studies are monitored in accordance with the current Data and Safety Monitoring Plan (dated 2001). The office is heavily involved with the assurance of appropriate institutional, legal, scientific, and regulatory review of all clinical research protocols conducted at St. Jude. A recent review of processes showed that St. Jude's clinical research infrastructure is superior to that of benchmarked institutions, and provides researchers with unique opportunities that are unavailable elsewhere. The effort placed in monitoring and organization has had significant positive impact on the quality of research conducted at St. Jude. As the number of clinical trials with external collaborating sites increases, resources to support those sites have also been added, including monitors/auditors who review study information on site. Upgrades to the clinical trials database and enrollment system are ongoing to meet current and future needs. To meet the future needs of clinical research, the institutional clinical trials infrastructure will continue to evolve. The Institutional Data and Safety Monitoring Plan is being revised to incorporate a more risk-based approach to monitoring and auditing. The monitoring program will be moved into Cancer Center Operations in order to allow for real time monitoring of key aspects of the research. A separate institutional auditing function will review clinical research studies at regular intervals. Restructuring of CPDMO functions in the context of the Cancer Center and Institution will allow us to capitalize on strengths and to be good stewards of institutional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-31
Application #
7802173
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
31
Fiscal Year
2009
Total Cost
$436,885
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Gibson, Todd M; Li, Chenghong; Armstrong, Gregory T et al. (2018) Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:3436-3444
Yang, Kai; Blanco, Daniel Bastardo; Chen, Xiang et al. (2018) Metabolic signaling directs the reciprocal lineage decisions of ?? and ?? T cells. Sci Immunol 3:
Ferrolino, Mylene C; Mitrea, Diana M; Michael, J Robert et al. (2018) Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms. Nat Commun 9:5064
Bjornard, Kari L; Gilchrist, Laura S; Inaba, Hiroto et al. (2018) Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health 2:744-754
Luo, Yi; Shao, Lijian; Chang, Jianhui et al. (2018) M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. Blood Adv 2:859-870
Peterson, Rachel K; Ashford, Jason M; Scott, Sarah M et al. (2018) Predicting parental distress among children newly diagnosed with craniopharyngioma. Pediatr Blood Cancer 65:e27287
Kumar, Rahul; Liu, Anthony P Y; Orr, Brent A et al. (2018) Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer 124:4168-4180
Rusch, Michael; Nakitandwe, Joy; Shurtleff, Sheila et al. (2018) Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun 9:3962
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Chamdine, Omar; Elhawary, Ghada Ahmad Saad; Alfaar, Ahmad Samir et al. (2018) The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst 34:431-439

Showing the most recent 10 out of 6764 publications